Plant Name: Mitracarpus scaber
Taxonomic Information:
Plant ID: NPO10026
Plant Latin Name: Mitracarpus scaber
Taxonomy Genus: Mitracarpus
Taxonomy Family: Rubiaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| ALPL; TDP1; BLM; HSD11B1; PGD; ALOX12; HSD11B2; HSD17B1; AKR1B1; HSD17B2; HSD17B10; TNKS; TNKS2; APEX1; | |
| BCL2; | |
| CDK6; CSNK2A1; | |
| CA2; CA12; CA14; CA7; CA4; | |
| ESR2; | |
| TYR; | |
| KDM4E; | |
| AHR; NFKB1; | |
| FUT7; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | P80365 | CHEMBL3746 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.708E-13 | 4.037E-09 | AKR1B1, ALOX12, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, HSD11B1, HSD11B2, HSD17B1, HSD17B10, HSD17B2, KDM4E, PGD, TYR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.431E-12 | 3.501E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.607E-11 | 3.313E-07 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.482E-10 | 1.083E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.110E-10 | 1.113E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.636E-08 | 2.392E-05 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.887E-08 | 2.515E-05 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.188E-07 | 6.997E-05 | ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP1A1, CYP1A2, HSD11B2, HSD17B2, NFKB1, TYR |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.189E-07 | 6.997E-05 | APEX1, CYP1A1, CYP1A2, CYP2C9, KDM4E |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.222E-07 | 7.002E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.516E-07 | 8.250E-05 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.053E-07 | 1.040E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 6.298E-07 | 2.881E-04 | CYP19A1, CYP1A1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.976E-07 | 3.545E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.653E-06 | 7.058E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.146E-06 | 8.497E-04 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 5.082E-06 | 1.756E-03 | AKR1B1, ALPL, APEX1, BCL2, CA2, CSNK2A1, CYP1A2, HSD11B2, NFKB1 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.040E-05 | 3.484E-03 | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, HSD11B1, HSD11B2, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.190E-05 | 3.927E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.311E-05 | 4.136E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.998E-05 | 5.879E-03 | AKR1B1, APEX1, BLM, CDK6, CYP1B1, NFKB1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.377E-05 | 6.637E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.377E-05 | 6.637E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.377E-05 | 6.637E-03 | CYP1A2, CYP2C9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.084E-22 | 3.980E-20 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA4, CA7, CA6, CA9, CA14 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.551E-11 | 9.873E-10 | MAOA, ALOX15, AKR1B1, ALOX12, PTGS2, CYP2C19, CYP3A4, CYP19A1, HSD17B10, HSD11B1, FUT7, ALDH2, HSD17B1, ALOX5, HSD17B2, XDH, GAA, PGD, TYR, CYP2C9, PKM, AKR1B10, CYP1A2, ALDH1A1, CYP1A1, ALPL, ALPI |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.088E-12 | 7.724E-10 | HSD11B1, HSD11B2, HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 6.415E-09 | 1.750E-07 | GSK3B, FLT3, DAPK1, PTGS2, HIF1A, NFKB1, AR, CDK6, CDK2, BCL2, AKT1, MAPK1, MET, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.968E-09 | 1.516E-07 | HSD17B1, ALOX5, HSD17B2, CYP1A1, CYP1B1, PTGS2, CYP19A1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.376E-09 | 1.516E-07 | CYP2C9, CYP2D6, MAOA, ALOX5, ALOX15, MAPK1, ALOX12, CYP2C19, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.075E-08 | 2.567E-07 | GSK3B, AR, CDK2, BCL2, AKT1, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.577E-09 | 1.750E-07 | HSD11B1, CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 5.371E-08 | 1.026E-06 | GSK3B, AKT1, MAPK1, MAPK14, ESR1, NFKB1, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.233E-08 | 6.861E-07 | PKM, FLT3, AKT1, MAPK1, TP53, MET, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.133E-07 | 1.665E-06 | GSK3B, BCL2, AKT1, MAPK1, PTPN11, MAPK14, TP53, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.918E-08 | 1.027E-06 | HSD11B1, CYP2C9, CYP2D6, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.853E-07 | 2.362E-06 | ABCC1, CDK6, PIM1, BCL2, CYP1B1, MAPK1, PTGS2, TP53, MET, NFKB1, MCL1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.133E-07 | 1.665E-06 | ABCC1, ADORA3, BCL2, AKT1, MAPK1, MAPK14, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.722E-07 | 3.950E-06 | PARP1, LMNA, BCL2, AKT1, MAPK1, TP53, NFKB1, MCL1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.855E-07 | 2.362E-06 | CDK6, CDK2, BCL2, AKT1, PTGS2, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.303E-07 | 6.642E-06 | GSK3B, CDK6, SYK, CDK2, BCL2, AKT1, MAPK1, TP53, MET, NFKB1, MCL1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 2.980E-07 | 3.349E-06 | GSK3B, CDK6, CSNK2A1, CDK2, AKT1, RAB9A, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 5.558E-07 | 5.308E-06 | GSK3B, SYK, CSNK2A1, CDK2, BCL2, AKT1, MAPK14, TP53, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.168E-07 | 5.196E-06 | CYP2C9, ALOX5, ALOX15, ALOX12, CYP2C19, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.060E-06 | 4.287E-05 | AKT1, MAPK1, PTPN11, MAPK14, TP53, HIF1A, ESR1, MET |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 9.810E-07 | 8.517E-06 | CYP2C9, MAOA, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.372E-06 | 1.048E-05 | CDK6, AKT1, MAPK1, PTPN11, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 6.512E-06 | 4.364E-05 | POLB, CDK6, PKM, SYK, CDK2, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 6.626E-06 | 4.364E-05 | CDK6, CDK2, BCL2, AKT1, MAPK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.163E-06 | 9.658E-06 | SLCO1B1, CA2, SLCO1B3, CYP3A4, CFTR, ABCG2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 9.168E-06 | 5.649E-05 | PIM1, BCL2, AKT1, MAPK1, MAPK14, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 5.687E-06 | 4.178E-05 | SYK, CSNK2A1, PARP1, BCL2, PTGS2, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.486E-07 | 2.968E-06 | CYP2C9, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 2.233E-05 | 1.153E-04 | ALOX5, BCL2, AKT1, MAPK1, MAPK14, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 7.883E-06 | 5.019E-05 | FLT3, PIM1, AKT1, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.233E-05 | 1.153E-04 | GSK3B, AKT1, MAPK1, TP53, ESR1, HIF1A |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.321E-06 | 1.048E-05 | ALDH2, MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.195E-05 | 7.136E-05 | GSK3B, BCL2, AKT1, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.626E-05 | 8.875E-05 | CDK6, AKT1, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 4.385E-05 | 2.094E-04 | GSK3B, AKT1, MAPK1, MAPK14, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 1.140E-04 | 5.186E-04 | THPO, PIM1, BCL2, AKT1, PTPN11, MCL1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.626E-05 | 8.875E-05 | AKT1, MAPK1, PTPN11, MET, HIF1A |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 2.662E-05 | 1.304E-04 | GSK3B, SYK, AKT1, MAPK1, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.509E-05 | 8.732E-05 | CYP2C9, CYP1A2, ALDH1A1, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.325E-05 | 1.169E-04 | CDK6, AKT1, MAPK1, TP53, MET |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 1.991E-04 | 7.923E-04 | GSK3B, AKT1, MAPK1, PLG, MAPK14, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.385E-04 | 6.153E-04 | BCL2, AKT1, MAPK1, HIF1A, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.450E-04 | 6.293E-04 | GSK3B, AKT1, MAPK1, MAPK14, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.886E-04 | 7.665E-04 | AKT1, MAPK1, MAPK14, PTGS2, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.807E-04 | 7.504E-04 | PTPN1, GSK3B, AKT1, PTPN11, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 2.183E-04 | 8.339E-04 | SYK, BCL2, AKT1, MAPK1, MAPK14, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 3.968E-04 | 1.353E-03 | HCAR2, AKT1, MAPK1, CFTR, NFKB1, TSHR |
| 09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 4.388E-04 | 1.436E-03 | SYK, AKT1, MAPK1, MAPK14, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.131E-04 | 5.186E-04 | GSK3B, AKT1, MAPK1, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 1.442E-03 | 4.111E-03 | AKT1, MAPK1, MAPT, MAPK14, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 1.512E-04 | 6.418E-04 | CDK6, AKT1, MAPK1, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.109E-04 | 8.223E-04 | AKT1, MAPK1, MAPK14, PTGS2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 3.209E-04 | 1.135E-03 | SYK, AKT1, MAPK1, MAPK14 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.697E-04 | 9.906E-04 | CDK6, AKT1, MAPK1, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.275E-03 | 3.807E-03 | CDK2, AKT1, MAPK1, MAPK14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.324E-03 | 3.892E-03 | AKT1, MAPK1, ESR1, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.763E-03 | 4.811E-03 | HPGD, FLT3, TP53, MET, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 1.988E-03 | 5.206E-03 | CSNK2A1, CDK2, PTPN11, TP53, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.704E-03 | 4.716E-03 | AKT1, MAPK1, MAPK14, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.209E-04 | 1.135E-03 | PTPN11, MAPK14, MET, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 4.211E-04 | 1.411E-03 | MAPK1, MAPK14, PTGS2, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.588E-03 | 4.462E-03 | AKT1, MAPK1, MAPK14, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 2.017E-03 | 5.206E-03 | ACHE, BCL2, AKT1, MAPK1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 2.908E-03 | 7.031E-03 | GSK3B, BCL2, AKT1, MAPK1, MET |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 2.842E-03 | 7.023E-03 | SYK, AKT1, MAPK1, MAPK14 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.435E-04 | 1.436E-03 | PTPN1, CSNK2A1, MAPK1, MET |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 3.473E-03 | 8.089E-03 | GSK3B, MAOA, AKT1, MAPK14 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.873E-03 | 8.806E-03 | CDK2, AKT1, MAPK1, MAPK14 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 3.013E-03 | 7.106E-03 | GSK3B, CDK6, CDK2, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.471E-03 | 6.293E-03 | AKT1, PTGS2, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 3.009E-03 | 7.106E-03 | AKT1, MAPK1, HIF1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 3.775E-03 | 8.686E-03 | MAPK1, MAPK14, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.599E-03 | 6.532E-03 | MAPK1, MAPK14, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00561 | Glycerolipid metabolism | 2.868E-03 | 7.023E-03 | AKR1B10, ALDH2, AKR1B1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05014 | Amyotrophic lateral sclerosis (ALS) | 1.889E-03 | 5.081E-03 | BCL2, MAPK14, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.001E-03 | 3.083E-03 | DAPK1, MAPK1, TP53 |
| 09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 1.231E-03 | 3.731E-03 | ABCC1, CFTR, ABCG2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 1.401E-03 | 4.054E-03 | CYP3A4, XDH, CES2 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 3.961E-04 | 1.353E-03 | AKR1B10, GAA, AKR1B1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 6.821E-04 | 2.136E-03 | AKR1B10, ALDH2, AKR1B1 |
| 09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 5.267E-04 | 1.677E-03 | POLB, PARP1, APEX1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00790 | Folate biosynthesis | 1.998E-03 | 5.206E-03 | ALPL, ALPI |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.259E-04 | 8.459E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; BCL2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; NFKB1; ACHE; BCL2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; HSD11B2; NFKB1; |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; BCL2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
